Neuren posts bumper sales for Rett syndrome drug
Neuren Pharmaceuticals has reported record US sales of its drug therapy for the treatment of Rett syndrome, Daybue, with full-year net sales soaring 97 per cent.
Neuren’s US development partner Acadia reported full-year sales of $US348.4 million, hitting the top end of guidance. Fourth quarter net sales of US$96.7 million was a record quarter since launch in April 2023.
Neuren forecast royalties of $56.2 million for 2024, up 110 per cent from 2023. “With 70 per cent of the 5500 to 5800 diagnosed Rett patients yet to try Daybue, there is substantial potential for growth in the US,” the company said.
From AFR
1 hr ago – 11.10AMNeuren posts bumper sales for Rett syndrome...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.280(2.28%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.52 | $12.73 | $12.26 | $8.152M | 652.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 665 | $12.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.55 | 235 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |